Onward Therapeutics
Manufacturing · France · 1-10 Employees
View Company Info for Free
Overview
Headquarters
77 Rue De Vaugirard, Paris, Ile-de-Franc...Website
www.onward-therapeutics.comRevenue
$6.2 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Onward Therapeutics
Onward Therapeutics is a development stage oncology company dedicated to identifying innovative technologies and creating breakthrough medicines for cancer treatment. The company is led by a skilled team in translational science and drug development, focusing on acquiring licenses for potential development candidates and forming partnerships with transformative technology platforms. With locations in Switzerland, France, and Taiwan, Onward Therapeutics aims to advance cancer care through strategic collaborations and innovative therapies. Their pipeline includes various projects such as OT-A201 and OT-C001, targeting significant advancements in oncology.Explore more
Onward Therapeutics Org Chart
CT
Senior Director, Corporate Development
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Onward Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Onward Therapeutics has new funding data
Click to see if Onward Therapeutics had a recent Job posting/layoffs
Onward Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Onward Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Onward Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Onward Therapeutics
Product Launch: Get notified when Onward Therapeutics launches new products
Check out if Onward Therapeutics is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Company Profile Activity
Activity Insights
Onward Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Onward Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Onward Therapeutics.
Onward Therapeutics Tech Stack
A closer look at the technologies used by Onward Therapeutics
Onward Therapeutics News & Media
Onward Therapeutics Exercises Exclusive Option and Signs Worldwide License Agreement with Institut du Cancer de Montpellier for Novel Onco-Metabolism Program
EPALINGES, Switzerland, Oct. 27, 2025 /PRNewswire/ -- Onward Therapeutics SA, a clinical stage oncology company, today announced that its French subsidiary, Onward Therapeutics France, has exercised its exclusive option and entered into a worldwide license agreement with Institut du...Onward Therapeutics Announces IMPD Approval for Its Subsidiary Emercell to Start Clinical Investigation of Allogeneic NK Cell Therapy OT-C001 in Combination with Rituximab
EPALINGES, Switzerland and PARIS, April 22, 2025 /PRNewswire/ -- Onward Therapeutics SA, a biotechnology company dedicated to advancing innovative cancer immunotherapies, announced that its subsidiary, Emercell SAS, has received Investigational Medicinal Product Dossier (IMPD) approval from the European Medicines Agency (EMA) to initiate a Phase 1 clinical trial of OT-C001, an allogeneic natural killer (NK) cell therapy, in combination with an anti-CD20 monoclonal antibody, Rituximab. The upcomiBiomunex Pharmaceuticals Announces the Start of a Phase 1 Clinical Trial for Its First-in-class Bispecific Antibody for the Treatment of Cancer
PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Biomunex Pharmaceuticals (Biomunex), a French biopharmaceutical company that develops cutting-edge immunotherapies through the discovery and development of bi- and multi-specific antibodies, generated from the BiXAb platform, for the treatment of cancer, announced today the enrollment in 2023 of the first patient in a Phase 1 clinical trial conducted by Onward Therapeutics SA (Onward Therapeutics). In preclinical studies, this antibody generated from BOnward Therapeutics Announces Enrollment of Phase 1 Clinical Trial of a Novel Bispecific Antibody (OT-A201) Targeting Two Immune Checkpoints
EPALINGES, Switzerland and PARIS, Jan. 24, 2024 /PRNewswire/ -- Onward Therapeutics SA (Onward Therapeutics), a global biotechnology company focused on developing innovative immunotherapies for cancer treatment, today announced that the phase 1 clinical trial of OT-A201 (Study No. A20101), a first-in-class bispecific antibody targeting two immune checkpoints is in progress. The study aims to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary anti-tumoral activit
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Onward Therapeutics
Sign Up For FreeTo access detailed company insights
Onward Therapeutics is a development stage oncology company dedicated to identifying innovative technologies and creating breakthrough medicines for cancer treatment. The company is led by a skilled team in translational science and drug development, focusing on acquiring licenses for potential development candidates and forming partnerships with t... Read More
